This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager.
Dismiss

Illumina tells EU judges it and Grail were ‘used as guinea pigs’ for new referral rules

By Natalie McNelis ( December 16, 2021, 09:59 GMT | Insight) -- Illumina told EU judges today that the European Commission had no right to seize jurisdiction over its acquisition of cancer-testing company Grail, and ran roughshod over its procedural rights. The acquisition is the first case under the commission’s new "Article 22" policy of accepting referrals from national competition authorities, even where the deal doesn’t meet normal jurisdictional thresholds in Europe.Illumina told EU judges today that the European Commission had no right to seize jurisdiction over its acquisition of cancer-testing company Grail, and ran roughshod over its procedural rights....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login